Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT00490789
Other study ID # TESSTAL
Secondary ID
Status Unknown status
Phase Phase 2
First received June 21, 2007
Last updated April 29, 2008
Start date October 2005
Est. completion date September 2009

Study information

Verified date April 2008
Source Cardiff University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.


Description:

Inherited mutations of the TSC1 or TSC2 gene cause tuberous sclerosis while acquired (somatic) mutations of either gene are associated with sporadic lymphangioleiomyomatosis (LAM). Renal angiomyolipomas are a feature of both disorders. TSC1 and TSC2 regulate signalling through the mammalian target of rapamycin (mTOR) pathway. Inhibition of mTOR may result in a decrease in size of TSC 1/2 assciated lesions. We are treating patients with tuberous sclerosis or sporadic LAM with the mTOR inhibitor rapamycin in a non-randomised, open label pilot study of safety and efficacy. Change in size of renal angiomyolipomas is the primary end point


Recruitment information / eligibility

Status Unknown status
Enrollment 14
Est. completion date September 2009
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- If female, documentation of negative pregnancy test prior to enrolment.

- Participants, including males, must use an effective form of contraception, whilst taking sirolimus and for twelve weeks after stopping the drug

- One or more renal angiomyolipomata of at least two centimetres or greater in largest diameter

- Adequate renal function :glomerular filtration rate > 40 ml/min

- Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria) or sporadic LAM (biopsy-proven or compatible high resolution chest CT scan and respiratory function tests.)

- Signed and dated informed consent

Exclusion Criteria:

- History of non-compliance or inability to give informed consent

- Significant haematological or hepatic abnormality (i.e. transaminase levels > 150 i.u./L serum albumin < 30 g/L, haematocrit< 30%, platelets < 100,000/ mm3, adjusted absolute neutrophil count < 1,500/mm3, total WBC < 3,000/ mm3)

- Greater than 1 g proteinuria daily

- Multiple bilateral AMLs, where individual lesions cannot be distinguished

- Renal haemorrhage within preceding year

- In those who have had a renal haemorrhage, known conservatively managed renal aneurysm(s) greater than 10mm

- Patients who have had embolisation for AML(s) within the preceding 6 months

- Patients who are unable to walk 100 metres on the flat

- Continuous requirement for supplemental oxygen

- Patients who have had or are being considered for organ transplant

- Uncontrolled hyperlipidaemia

- Intercurrent infection at initiation of Sirolimus

- Surgery within last 2 months

- Pregnant or lactating women

- Use of an investigational drug within the last 30 days

- Change in anti epileptic drug medication within the last 3 months

- Likely to need vaccination e.g. for travel during the course of the trial (except for influenza vaccine in patients with LAM)

- Current usage of strong inhibitors of CYP3AE ( such as ketoconazole, voriconazole, itraconazole, tilithromycin or clarithromycin) or strong inducers (such as rifampicin or rifabutin)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
sirolimus
daily oral sirolimus with dosage individualised by trough blood levels

Locations

Country Name City State
United Kingdom Royal Sussex County Hospital Brighton
United Kingdom University Hospital of Wales Cardiff Wales
United Kingdom City Hospital Nottingham

Sponsors (6)

Lead Sponsor Collaborator
Cardiff University Royal Sussex County Hospital, St Georges Hospital Medical School, The Tuberous Sclerosis Association, University of Nottingham, Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary longest diameter of renal angiomyolipomas assessed by MRI scan, toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 assessments at baseline and 2,6,12 and 24 months
Primary toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events throughout study
Secondary respiratory function tests (FEV1, FVC, DLCO), cognitive function (memory, executive skills) 2 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Recruiting NCT03422367 - JASPER Early Intervention for Tuberous Sclerosis N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT02104011 - Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Phase 2
Recruiting NCT02461459 - Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
Completed NCT01526356 - Topical Rapamycin to Erase Angiofibromas in TSC Phase 2
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Terminated NCT01092208 - Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Active, not recruiting NCT01954693 - A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Phase 2
Completed NCT03826628 - Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Phase 2/Phase 3
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT05286632 - KidneYou - Innovative Digital Therapy N/A
Withdrawn NCT04344626 - Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery N/A
Recruiting NCT05199402 - Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
Recruiting NCT00001975 - Study of Skin Tumors in Tuberous Sclerosis